Pfizer’s COVID-19 vaccine gets green light from USFDA for emergency use authorisation for inoculation in people aged 16 years and older. Healthcare workers and elderly people in long-term care facilities are expected to be the main recipients of the first round of 2.9 million doses, said the U.S government.
The vaccine was developed by Pfizer in association with its German partner BioNTech, which was shown to be 95% effective in preventing the disease in a late-stage clinical trial.
A shot similar to Pfizer and BioNTech’s made by Moderna Inc. is expected to gain US clearance next week, providing the country with a potent combination for beating back the pathogen.
The Pfizer/BioNTech vaccine was first approved in Britain earlier in December 2020, and UK residents began receiving the shots on Tuesday. Canada also authorized the vaccine and expects to start inoculations next week.
The Mexican government’s medical safety commission also had cleared the emergency use of the Pfizer-BioNTech coronavirus vaccine yesterday.
President Donald Trump said late on Friday after the US FDA approved Pfizer Inc’s COVID-19 vaccine that the first shot would be administered in the United States in less than 24 hours.